PLYX — POLARYX THERAPEUTICS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.06 | — | -0.05 | -0.08 | 2 | +1−1 |
| Mar 2027 | -0.07 | — | -0.06 | -0.08 | 2 | +1 |
| Jun 2027 | -0.06 | — | -0.06 | -0.07 | 2 | +2 |
| Sep 2027 | -0.06 | — | -0.06 | -0.07 | 2 | +2 |
| Dec 2027 | -0.06 | — | -0.06 | -0.07 | 2 | +1 |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.21 | — | -0.18 | -0.23 | 2 | +1−1 |
| Dec 2027 | -0.27 | — | -0.24 | -0.30 | 2 | +2 |
| Dec 2028 | -0.25 | — | -0.25 | -0.25 | 1 | +1 |
| Dec 2029 | -0.23 | — | -0.23 | -0.23 | 1 | +1 |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 13 SEC-registered investment managers reported holding PLYX (POLARYX THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $4.30M across 2.08M shares. That is -5.0% by share count (-106.10K shares) versus the previous quarter, while reported value moved -26.0%. Ownership is concentrated: the five largest holders account for 95.5% of reported value and the top ten for 99.7%.
Compared with the prior quarter, 2 opened new positions, 2 added to existing stakes, 4 trimmed, 3 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of POLARYX THERAPEUTICS INC (PLYX) include VANGUARD CAPITAL MANAGEMENT LLC, Millennium Management, MILLENNIUM MANAGEMENT LLC, ranked by reported 13F value among the 22 institutional holders on this page.
PLYX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 13 | 2.08M | $4.30M | -4.5% |
| Q2 2026 | 13 | 2.31M | $6.13M | -0.5% |
| Q1 2026 | 15 | 2.39M | $18.10M | — |
Over the 3 quarters shown, institutional share counts decreased 13% in aggregate (Q1 2026 → Q3 2026).
Top Institutional Holders (Q3 2026) — 13 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 1.66M | $3.43M | 0.00% | Hold | |
| 138.76K | $287.41K | 0.00% | Reduce | |
| 80.32K | $166.26K | 0.00% | Reduce | |
| 68.00K | $140.77K | 0.00% | Add | |
| 41.01K | $84.89K | 0.00% | Hold | |
| 33.10K | $68.00K | 0.00% | Reduce | |
| 27.99K | $57.93K | 0.00% | Hold | |
| 10.43K | $21.58K | 0.00% | New | |
| 7.73K | $20.55K | 0.00% | Hold | |
| 6.32K | $13.08K | 0.00% | Hold | |
| 4.36K | $9.02K | 0.00% | Add | |
| 1.85K | $3.84K | 0.00% | Reduce | |
| 9 | $19 | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 13 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 1.66M | $4.41M | 0.00% | Hold | |
| 171.00K | $455.08K | 0.00% | New | |
| 171.00K | $455.08K | 0.00% | Hold | |
| 105.07K | $279.49K | 0.00% | Hold | |
| 82.09K | $218.00K | 0.00% | New | |
| 41.01K | $109.09K | 0.00% | Hold | |
| 31.44K | $83.63K | 0.00% | New | |
| 27.99K | $74.44K | 0.00% | Hold | |
| 7.73K | $20.55K | 0.00% | New | |
| 6.32K | $16.81K | 0.00% | Hold | |
| 3.00K | $7.99K | 0.00% | Add | |
| 1.28K | $3.41K | 0.00% | Reduce | |
| 189 | $503 | 0.00% | New |
Q1 2026 — 15 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 1.66M | $12.54M | 0.00% | New | |
| 170.67K | $1.29M | 0.00% | New | |
| 127.53K | $964.09K | 0.00% | New | |
| 127.53K | $964.09K | 0.00% | New | |
| 104.56K | $790.44K | 0.00% | New | |
| 58.10K | $439.27K | 0.00% | New | |
| 41.01K | $310.05K | 0.00% | New | |
| 27.99K | $211.58K | 0.00% | New | |
| 25.88K | $195.66K | 0.00% | New | |
| 13.48K | $101.93K | 0.00% | New | |
| 13.48K | $101.90K | 0.00% | New | |
| 12.41K | $93.79K | 0.00% | New | |
| 6.32K | $47.76K | 0.00% | New | |
| 5.54K | $41.91K | 0.00% | New | |
| 1.78K | $13.46K | 0.00% | New |
New Positions (Q3 2026)
- Cerity Partners LLC 10.43K sh · $21.58K
- BARCLAYS PLC 9 sh · $19
Fully Exited (vs previous quarter)
- GEODE CAPITAL MANAGEMENT, LLC sold 171.00K sh · $455.08K
- JANE STREET GROUP, LLC sold 31.44K sh · $83.63K
- Fortitude Family Office, LLC sold 189 sh · $503
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.66M | 1.66M | 1.66M |
| Geode Capital Management | 138.76K | 171.00K | 170.67K |
| VANGUARD FIDUCIARY TRUST CO | 80.32K | 105.07K | 104.56K |
| STATE STREET CORP | 68.00K | — | 58.10K |
| BlackRock Inc | 41.01K | 41.01K | 41.01K |
| HRT FINANCIAL LP | 33.10K | 82.09K | — |
| Northern Trust Corp | 27.99K | 27.99K | 27.99K |
| Cerity Partners LLC | 10.43K | — | — |
| Allworth Financial LP | 7.73K | 7.73K | — |
| Vanguard Global Advisers, LLC | 6.32K | 6.32K | 6.32K |
| UBS Group AG | 4.36K | 1.28K | 13.48K |
| Tower Research Capital LLC (TRC) | 1.85K | 3.00K | 1.78K |
| BARCLAYS PLC | 9 | — | — |
| Millennium Management | — | — | 127.53K |
| MILLENNIUM MANAGEMENT LLC | — | — | 127.53K |
| GEODE CAPITAL MANAGEMENT, LLC | — | 171.00K | — |
| Bank of America Corp | — | — | 25.88K |
| Goldman Sachs Group | — | — | 13.48K |
| Squarepoint Ops LLC | — | — | 12.41K |
| JANE STREET GROUP, LLC | — | 31.44K | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold PLYX?
As of 2026-Q3, 13 institutional funds reported holding PLYX (POLARYX THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $4.30M.
How many shares of PLYX do institutions own?
13F filers reported 2.08M shares of PLYX, worth $4.30M in aggregate at the end of 2026-Q3.
Is institutional ownership of PLYX rising or falling?
Share counts moved -5.0% versus the prior quarter — distribution.
Who are the top institutional holders of PLYX?
The largest 13F holders are VANGUARD CAPITAL MANAGEMENT LLC, Millennium Management, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Geode Capital Management; the top 25 are ranked at the top of this page.
Who are the major shareholders of POLARYX THERAPEUTICS INC?
The major shareholders of POLARYX THERAPEUTICS INC (PLYX) by reported 13F value are VANGUARD CAPITAL MANAGEMENT LLC, Millennium Management, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Geode Capital Management, among 22 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.